IMRICOR MEDICAL SYSTEMS INC (IMR)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMR

IMR - IMRICOR MEDICAL SYSTEMS INC

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -1.15
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.84

09 Jul
2026

0.015

OPEN

$1.83

0.82%

HIGH

$1.92

84,202

LOW

$1.80

TARGET
$2.94 59.8% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
IMR: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 7.2 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-12.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.5 M
Book Value Per Share xxxxxxxxxxxxxxx5.4
Net Operating Cash Flow xxxxxxxxxxxxxxx-29.6 M
Net Profit Margin xxxxxxxxxxxxxxx-8,661.57 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-1,463.63 %
Return on Invested Capital xxxxxxxxxxxxxxx-131.50 %
Return on Assets xxxxxxxxxxxxxxx-75.84 %
Return on Equity xxxxxxxxxxxxxxx-1,463.63 %
Return on Total Capital xxxxxxxxxxxxxxx-89.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-30.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx18 M
Long Term Debt xxxxxxxxxxxxxxx21 M
Total Debt xxxxxxxxxxxxxxx39 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx61 M
Price To Book Value xxxxxxxxxxxxxxx28.42

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.7 M
Capex % of Sales xxxxxxxxxxxxxxx148.57 %
Cost of Goods Sold xxxxxxxxxxxxxxx4 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx32 M
Research & Development xxxxxxxxxxxxxxx17 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

03/07/2026

1

Speculative Buy

$2.94

59.78%

Imricor Medical Systems has received US FDA clearance for its NorthStar mapping system and Diagnostic Catheter for use in paediatric patients, opening up a new commercial sales opportunity.

Morgans lauds the innovative technology that has its initial application in cardiac ablation procedures, while the clinical trials nbsp;underway have potential to significantly increase the addressable market.

The clearances from the FDA are strategically important as they expand the opportunity beyond adult electrophysiology procedures and into paediatric cardiac interventions. Speculative Buy rating maintained. Target rises to $2.94 from $2.61.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -7.21 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -5.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Taylor Collison

25/05/2026

2

Outperform

$3.45

87.50%

Taylor Collison reiterates an Outperform rating for Imricor Medical Systems, with its target price increased to $3.45 from $2.78 following channel checks at the Heart Rhythm Society 2026 conference.

The broker observed growing physician consensus regarding the clinical utility of interventional cardiac magnetic resonance in visualising soft tissue and guiding treatments for ventricular arrhythmias.

The proprietary technology addresses critical visualisation gaps in standard electrophysiology, particularly around abnormal anatomy associated with longer procedure times.

Upward revisions to near-term projections for FY27-FY28 US atrial flutter procedures and laboratory installations drive revenue estimate upgrades.

The core investment thesis remains supported by a powerful convergence of clinician advocacy, external clinical data, and tangible regulatory momentum, the broker notes.

FORECAST
Taylor Collison forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -17.35 cents.
Taylor Collison forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -13.67 cents.

Jarden

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Extra Coverage Research History >

IMR STOCK CHART

FNArena News on IMR

1
Australian Broker Call *Extra* Edition – Jul 06, 2026

Jul 06 2026 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – May 25, 2026

May 25 2026 - Daily Market Reports
3
In Brief: Imricor, COG Financial & Alicantro

May 22 2026 - Weekly Reports
4
Australian Broker Call *Extra* Edition – May 21, 2026

May 21 2026 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – May 19, 2026

May 19 2026 - Daily Market Reports

Latest Medical Equipment & Devices News

1
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
2
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
3
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
4
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
5
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
6
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
7
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
8
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
9
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
10
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia